These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 27900363)

  • 1. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
    Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
    Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.
    Gupta S; Vanderbilt CM; Cotzia P; Arias-Stella JA; Chang JC; Zehir A; Benayed R; Nafa K; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME; Ross DS
    J Mol Diagn; 2019 Mar; 21(2):307-317. PubMed ID: 30576871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
    Budczies J; Denkert C; Győrffy B; Schirmacher P; Stenzinger A
    BMC Med Genomics; 2017 Dec; 10(1):74. PubMed ID: 29212506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Eur J Cancer; 2018 May; 94():179-186. PubMed ID: 29571084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular driver alterations and their clinical relevance in cancer of unknown primary site.
    Löffler H; Pfarr N; Kriegsmann M; Endris V; Hielscher T; Lohneis P; Folprecht G; Stenzinger A; Dietel M; Weichert W; Krämer A
    Oncotarget; 2016 Jul; 7(28):44322-44329. PubMed ID: 27322425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.
    Wang X; Beharry A; Sheffield BS; Cheema PK
    Oncologist; 2023 Jun; 28(6):474-478. PubMed ID: 36933203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
    Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
    Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
    Balko JM; Schwarz LJ; Luo N; Estrada MV; Giltnane JM; Dávila-González D; Wang K; Sánchez V; Dean PT; Combs SE; Hicks D; Pinto JA; Landis MD; Doimi FD; Yelensky R; Miller VA; Stephens PJ; Rimm DL; Gómez H; Chang JC; Sanders ME; Cook RS; Arteaga CL
    Sci Transl Med; 2016 Apr; 8(334):334ra53. PubMed ID: 27075627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.
    Van Roosbroeck K; Ferreiro JF; Tousseyn T; van der Krogt JA; Michaux L; Pienkowska-Grela B; Theate I; De Paepe P; Dierickx D; Doyen C; Put N; Cools J; Vandenberghe P; Wlodarska I
    Genes Chromosomes Cancer; 2016 May; 55(5):428-41. PubMed ID: 26850007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.
    Chen M; Andreozzi M; Pockaj B; Barrett MT; Ocal IT; McCullough AE; Linnaus ME; Chang JM; Yearley JH; Annamalai L; Anderson KS
    Mod Pathol; 2017 Nov; 30(11):1516-1526. PubMed ID: 28752839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy induces enrichment of CD47
    Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
    Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
    Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
    Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
    Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer of Unknown Primary in the Molecular Era.
    Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
    Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer.
    Nakayama Y; Mimura K; Tamaki T; Shiraishi K; Kua LF; Koh V; Ohmori M; Kimura A; Inoue S; Okayama H; Suzuki Y; Nakazawa T; Ichikawa D; Kono K
    Int J Oncol; 2019 Jun; 54(6):2030-2038. PubMed ID: 31081058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.
    Rassy E; Boussios S; Pavlidis N
    Eur J Clin Invest; 2021 Sep; 51(9):e13583. PubMed ID: 33970501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.